Headlines

Madrigal Pharmaceuticals Announces Publication in The Lancet of Positive Phase 2 Results for Resmetirom (MGL-3196) for the Treatment of Non-alcoholic Steatohepatitis (NASH)
November 11, 2019

Madrigal Pharmaceuticals Reports 2019 Third Quarter Results
November 6, 2019

Madrigal Pharmaceuticals Reports 2019 Second Quarter Results
August 7, 2019

Press Release History